SCHEMBL2020998

SCHEMBL2020998

CCN(CC1CC1)C(=O)c1ccc2[nH]c3c(c2c1)CC(C1CCOCC1)CC3

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 12/20 0.49
KMT2A Q03164 2/20 0.45
HTR1B P28222 3/20 0.45
HTR1A P08908 2/20 0.45
HTR1D P28221 1/20 0.45
MEN1 O00255 1/20 0.43
RAB9A P51151 1/20 0.43
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
DRD2 P14416 1/20 0.42
DRD4 P21917 1/20 0.42
HTR1E P28566 1/20 0.42
HTR7 P34969 1/20 0.42
OPRM1 P35372 1/20 0.42
TMEM97 Q5BJF2 1/20 0.42
CNR2 P34972 2/20 0.41
CYP2C9 P11712 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2018448 0.86 CNR1 (0.60) CNR1HTR1BHTR1AHTR1DRAB9A
SCHEMBL2017142 0.85 CNR1 (0.68) CNR1HTR1BHTR1AHTR1DCNR2
SCHEMBL2020454 0.85 KMT2A (0.52) CNR1KMT2AHTR1BHTR1AHTR1D
SCHEMBL2016008 0.80 KMT2A (0.65) KMT2AHTR1BHTR1AHTR1DMEN1
SCHEMBL2045339 0.79 KMT2A (0.45) CNR1KMT2AHTR1BHTR1AHTR1D
SCHEMBL2020894 0.79 HTR1B (0.56) CNR1KMT2AHTR1BHTR1AHTR1D
SCHEMBL12574206 0.79 KMT2A (0.69) KMT2AHTR1BHTR1AHTR1DMEN1
SCHEMBL12574208 0.79 KMT2A (0.69) KMT2AHTR1BHTR1AHTR1DMEN1
SCHEMBL2018573 0.79 KMT2A (0.69) KMT2AHTR1BHTR1AHTR1DMEN1
SCHEMBL2045340 0.71 HTR1B (0.48) CNR1KMT2AHTR1BHTR1AHTR1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110160180-A1 Cannabinoid Receptor Ligands ASTRAZENECA AB (SE) 2011-06-30 US disclosed
US-20090062251-A1 Novel Compounds 002 ASTRAZENECA AB (SE) 2009-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062251-A1 Novel Compounds 002 OPRL1, OPRK1, OPRM1 CNR1 17/4885KMT2A 2567/4885HTR1B 269/4885
US-20110160180-A1 Cannabinoid Receptor Ligands CNR1, CNR2, OPRL1 CNR1 1/4885KMT2A 2050/4885HTR1B 159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.